Trial master file
In order to comply with government regulatory requirements pertinent to clinical trials, every organization involved in clinical trials must maintain and store certain documents, images and content related to the clinical trial.
≈ 9 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
In order to comply with government regulatory requirements pertinent to clinical trials, every organization involved in clinical trials must maintain and store certain documents, images and content related to the clinical trial. Depending on the regulatory jurisdiction, this information may be stored in the Trial Master File or TMF, which today takes the form of an electronic trial master file (eTMF).
The International Conference on Harmonization (ICH) published a consolidated guidance for industry on Good Clinical Practice in 19961 with the objective of providing a unified standard for the European Union, Japan, and the United States of America to facilitate mutual acceptance of clinical data by the regulatory authorities in those jurisdictions. This guidance document established the requirement across all ICH regions to establish trial master files containing essential documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced.[2 ] In some jurisdictions, for example the USA, there is no specific requirement for a trial master file.
However, if the regulatory authority requires ICH GCP to be followed, then there is consequently a requirement to create and maintain a trial master file.[2 ]
In order to comply with government regulatory requirements pertinent to clinical trials, every organization involved in clinical trials must maintain and store certain documents, images and content related to the clinical trial. Depending on the regulatory jurisdiction, this information may be stored in the Trial Master File or TMF, which today takes the form of an electronic trial master file (eTMF).
The International Conference on Harmonization (ICH) published a consolidated guidance for industry on Good Clinical Practice in 1996 with the objective of providing a unified standard for the European Union, Japan, and the United States of America to facilitate mutual acceptance of clinical data by the regulatory authorities in those jurisdictions. This guidance document established the requirement across all ICH regions to establish trial master files containing essential documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced.
[2 ] In some jurisdictions, for example the USA, there is no specific requirement for a trial master file. However, if the regulatory authority requires ICH GCP to be followed, then there is consequently a requirement to create and maintain a trial master file.
[2 ] In September 2013 non-profit CareLex initiated an eTMF standards initiative under the OASIS standards organization to develop a consistent, machine-readable content classification model for eTMFs. [8 ] This initiative did not receive industry support and is now effectively dismantled.
The TMF contains the trial sponsor’s and participating investigators’ set of content which individually and collectively permit the evaluation of the conduct of a clinical trial and the quality of the data produced. These documents serve to demonstrate compliance with the standards of GCP and with all applicable regulatory requirements.
[1] It is part of the evidence provided for regulatory inspection that verifies that the members of the trial team: ensured subject protection, compliance with regulations/Good Clinical Practice, and that scientifically robust benefit-risk data was produced. While ICH GCP E6 details the minimum essential documents, it addresses only a sub-set of TMF content that is required to be created and available for inspection.
Documentation requirements for the set-up and maintenance of quality systems, electronic systems, safety monitoring, and proof of an adequate and well-controlled trial, to name a few, exist in various regulations across many countries or regions, but are not explicitly described in ICH GCP E6. Since there was no comprehensive, common industry model or best practice for a TMF, the objective of the TMF RM is to provide a single, unified interpretation of the regulations of the ICH regions as a document-type listing which would be accepted by all clinical trial stakeholders and which can be adopted or adapted by any company, institution or organization.
It does not provide guidance on the process by which the content is created, managed or retained. TMF Reference Model shortcomings As of May 2013, the TMF RM v2.0 was made available in an electronic spreadsheet format which is suitable for human viewing. While the TMF RM is acceptable for paper TMFs, there is no support for TMF content exchange between computer systems.
As the TMF RM is not a standard and is therefore not fixed, the TMF Model allows for flexibility in approach and any aspect of the model can be changed to suit an individual user's needs. Whilst this benefits the individual user, it results in variances in use and interpretation from one company to another.
One issue with the use of the TMF RM as an eTMF classification model relates to duplicate artifact names in the TMF RM. The current release of the TMF RM v3.0 contains several duplicate artifact names such as 'Communications' or 'General', each with different contexts and uses but the same name, which makes the TMF artifact names more challenging to implement in eTMF search and retrieval where a unique set of search results is desired.[[Database| [9] A second issue with the TMF RM relates to the length of the TMF RM artifact names - one artifact name is more than 64 characters.
Different file systems have different limits on the depth of the filename path, creating potential problems and limitations based on the file system hierarchy in use.[[File system| [10] Thirdly, with respect to the use of the TMF Reference Model as a database schema, the TMF RM v3.0 spreadsheet cannot be used without manual modification as a classification taxonomy in an electronic database.[[Database| [11] Electronic systems which are not based on interoperability standards are often unable to communicate with other systems or applications.[[Metadata| [12] The TMF RM currently lacks a controlled vocabulary based on published standards, which means that content indexed with the TMF RM artifact names and terms could return duplicate records, incorrect records or possibly no records at all if the model is not implemented appropriately.[[Controlled vocabulary| [13] The TMF RM doesn't provide standards-based methods to exchange the TMF model except for exchanging spreadsheet copies of TMF models. Today internet standards such as those promoted by the W3C are utilized for interoperable electronic exchange over legacy manual information exchange approaches.
Development of eTMF Content Exchange Standards and Protocols In an effort to assure interoperability of eTMF data among clinical trial stakeholders, in September 2013 non-profit CareLex initiated an eTMF standards initiative under the OASIS Open standards development organization for the development of a global eTMF ISO standard supporting seamless eTMF content exchange and portability. CareLex and SureClinical Inc are the founding sponsors of the eTMF standards initiative, with participation on the curation of a controlled vocabulary by the National Cancer Institute.
The stated objective of the eTMF standards initiative is to "define an open, internationally recognized standard that will assure information interoperability among clinical trial stakeholders in the BioPharma industry." According to minutes from the OASIS eTMF standard Technical Committee, the standards initiative is coordinating the efforts of clinical trial sponsors, CRO’s, research organizations, and vendors to develop an ISO standard.
This effort did not receive industry support and has now been dismantled and replaced by the TMF Reference Model Exchange Mechanism. As of February 2014, a partial list of members in the OASIS eTMF Standard Technical Committee includes CareLex, EMC, Forte Research, HL7, Mayo Clinic, Oracle, Paragon Solutions, Safe-BioPharma, SterlingBio, and SureClinical.
National Cancer Institute worked with the OASIS team to curate eTMF terms. The Technical Committee was closed by TC Administration without publication of a standard on 17 November 2017 and is no longer active.
In June 2018, the TMF Reference Model project team published a specification and an example XML exchange file for an eTMF Exchange Mechanism Standard at the DIA Global Meeting in Boston, USA. Use of this standard will help facilitate the exchange of TMF content between systems. Effective from April 27, 2022 the TMF Reference Model ceased to be affiliated with DIA and transferred affiliation to the CDISC standards organization.
Under CDISC, the intention is to develop the TMF Reference Model as a CDISC-certified standard. In April 2014, the European Parliament approved Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, repealing Directive 2001/20/EC.
[17 ] Article 57 of the Regulation requires that the TMF "shall at all times contain the essential documents relating to that clinical trial which allow verification of the conduct of a clinical trial and the quality of the data generated", confirming that the trial master file should be maintained contemporaneously. Article 58 requires that "the sponsor and investigator shall archive the content of the clinical trial master file for at least 25 years after the end of the clinical trial."
This requirement defines a minimum retention period across the EU for all clinical trial master files, irrespective of whether the data subsequently supports a marketing authorization approval. 2. EU Parliament Directive 2005/28/EC 63 Chapter 4 3.
US FDA Guidance for Industry 4. TMF Reference Model 2.0 5. European Medicines Agency, 9.
Problems found with Trial Master Files from GCP inspections, Jan 2013 6. European EC Regulations
Text derived from https://en.wikipedia.org/w/index.php?oldid=1322357119 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “Trial master file” publication date (×1) · confidence 0.95 revision URL